Phase I/II Trial of Combination Plerixafor (AMD3100) and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Plerixafor (Primary) ; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Dana-Farber Cancer Institute
- 31 Jul 2017 Planned End Date changed from 1 Mar 2017 to 1 Dec 2017.
- 18 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Mar 2017.
- 19 Feb 2016 Planned End Date changed from 1 Aug 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History